Detected ·
Oak Hill Bio
——
Oak Hill Bio raised $32.5M in Series A co-led by Balyasny Asset Management, Janus Henderson Investors, and venBio to advance rugonersen into Phase 3 development for Angelman syndrome.
- Website
- www.oakhillbio.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-06-01 16:07:06 UTC
- Signal ID
- 825714e5-45bb-4b98-8c76-417c400fa8f3
As the API returns it
{
"id": "825714e5-45bb-4b98-8c76-417c400fa8f3",
"created_at": "2026-06-01T16:07:06.200132Z",
"company_name": "Oak Hill Bio",
"company_website_url": "www.oakhillbio.com",
"company_linkedin_url": "https://www.linkedin.com/company/oak-hill-bio",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Oak Hill Bio raised $32.5M in Series A co-led by Balyasny Asset Management, Janus Henderson Investors, and venBio to advance rugonersen into Phase 3 development for Angelman syndrome.*"
}